Exact Mass: 676.1314

Exact Mass Matches: 676.1314

Found 34 metabolites which its exact mass value is equals to given mass value 676.1314, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

5-O-phosphonoadenylyl-(3->5)-adenosine

5-O-phosphonoadenylyl-(3->5)-adenosine

C20H26N10O13P2 (676.1156)


   

Diadenosine diphosphate

{[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}[({[(2R,3S,4R,5S)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy}(hydroxy)phosphoryl)oxy]phosphinic acid

C20H26N10O13P2 (676.1156)


Diadenosine diphosphate is a member of the diadenosine polyphosphates. Diadenosine diphosphate is typically synthesized from ADP-ribosyl cyclases. Diadenosine polyphosphates are members of a group of dinucleoside polyphosphates that are ubiquitous, naturally occurring molecules. They form a recently identified class of compounds derived from ATP and consist of two adenosine molecules bridged by up to six phosphate groups. These compounds are stored in high concentrations in platelet dense granules and are released when platelets become activated. Some of the compounds promote platelet aggregation, while others are inhibitory. Possible roles as neurotransmitters, extracellular signalling molecules or alarmones secreted by cells in response to physiologically stressful stimuli have been postulated. Recent studies suggest a role for these compounds in atrial and synaptic neurotransmission. Studies using isolated mesenteric arteries indicate an important role of phosphate chain length in determining whether diadenosine polyphosphates produce vasodilatation or vasoconstriction, but in the coronary circulation, diadenosine polyphosphates generally produce vasodilatation via mechanisms thought to involve release of NO or prostacyclin (PGI2). They produce cardiac electrophysiological effects by altering ventricular refractoriness at submicromolar concentrations and reduce heart rate. Mechanisms involving KATP channels have been proposed in addition to the involvement of P1- and P2-purinergic receptors and the specific diadenosine polyphosphate receptor identified on isolated cardiac myocytes. Clinical evidence suggests a role for diadenosine polyphosphates in hypertensive patients and those with the Chediak-Higashi syndrome. (PMID: 10434992) [HMDB] Diadenosine diphosphate is a member of the diadenosine polyphosphates. Diadenosine diphosphate is typically synthesized from ADP-ribosyl cyclases. Diadenosine polyphosphates are members of a group of dinucleoside polyphosphates that are ubiquitous, naturally occurring molecules. They form a recently identified class of compounds derived from ATP and consist of two adenosine molecules bridged by up to six phosphate groups. These compounds are stored in high concentrations in platelet dense granules and are released when platelets become activated. Some of the compounds promote platelet aggregation, while others are inhibitory. Possible roles as neurotransmitters, extracellular signalling molecules or alarmones secreted by cells in response to physiologically stressful stimuli have been postulated. Recent studies suggest a role for these compounds in atrial and synaptic neurotransmission. Studies using isolated mesenteric arteries indicate an important role of phosphate chain length in determining whether diadenosine polyphosphates produce vasodilatation or vasoconstriction, but in the coronary circulation, diadenosine polyphosphates generally produce vasodilatation via mechanisms thought to involve release of NO or prostacyclin (PGI2). They produce cardiac electrophysiological effects by altering ventricular refractoriness at submicromolar concentrations and reduce heart rate. Mechanisms involving KATP channels have been proposed in addition to the involvement of P1- and P2-purinergic receptors and the specific diadenosine polyphosphate receptor identified on isolated cardiac myocytes. Clinical evidence suggests a role for diadenosine polyphosphates in hypertensive patients and those with the Chediak-Higashi syndrome. (PMID: 10434992).

   

Adenylyl-(5-2)-5-adenylsaeure|D,D-pA(2-5)pA|p5A2p5A|pA2p5A|pA2pA

Adenylyl-(5-2)-5-adenylsaeure|D,D-pA(2-5)pA|p5A2p5A|pA2p5A|pA2pA

C20H26N10O13P2 (676.1156)


   

epiphyllic acid-7-O-beta-glucoside-10,5-O-shikimic acid ester

epiphyllic acid-7-O-beta-glucoside-10,5-O-shikimic acid ester

C31H32O17 (676.1639)


   

Griseorhodin A tetraacetate

Griseorhodin A tetraacetate

C33H24O16 (676.1064)


   

Caraphenol A

(10S,11S,19R)-3,11,19-tris(4-hydroxyphenyl)-4,12,20-trioxaheptacyclo[16.6.1.12,5.110,13.021,25.09,27.017,26]heptacosa-1(25),2,5,7,9(27),13,15,17(26),21,23-decaene-7,15,23-triol

C42H28O9 (676.1733)


   

6-O-{3-methoxy-4-O-beta-[6-O-(3-mercapto-5methoxy-4-O-methylcarboxy)phenyl]glucopyranosyl}phenyl beta-glucopyranose|rhamnakoside B

6-O-{3-methoxy-4-O-beta-[6-O-(3-mercapto-5methoxy-4-O-methylcarboxy)phenyl]glucopyranosyl}phenyl beta-glucopyranose|rhamnakoside B

C28H36O17S (676.1673)


   

beta-Naphthocyclinon

beta-Naphthocyclinon

C35H32O14 (676.1792)


   

Diadenosine diphosphate

P(1),P(2)-Diadenosine-5-pyrophosphate

C20H26N10O13P2 (676.1156)


   

chromium(3+),3-(2-ethylhexoxy)propan-1-amine,hydron,(2Z)-2-[(5-nitro-2-oxido-3-sulfonatophenyl)hydrazinylidene]-3-oxo-N-phenylbutanimidate,hydroxide

chromium(3+),3-(2-ethylhexoxy)propan-1-amine,hydron,(2Z)-2-[(5-nitro-2-oxido-3-sulfonatophenyl)hydrazinylidene]-3-oxo-N-phenylbutanimidate,hydroxide

C27H38CrN5O10S (676.1744)


   
   

ZINCMESO-TETRAPHENYLPORPHINE

ZINCMESO-TETRAPHENYLPORPHINE

C44H28N4Zn (676.1605)


   

Deoxydiguanosine diphosphosphate

Deoxydiguanosine diphosphosphate

C20H26N10O13P2 (676.1156)


   

Diadenosine 5,5-diphosphate

Diadenosine 5,5-diphosphate

C20H26N10O13P2 (676.1156)


   

Zinc tetraphenylporphyrin

Zinc tetraphenylporphyrin

C44H28N4Zn (676.1605)


   

Zinc, [5,10,15,20-tetraphenyl-21H,23H-porphinato(2-)-kappaN21,kappaN22,kappaN23,kappaN24]-, (SP-4-1)-

Zinc, [5,10,15,20-tetraphenyl-21H,23H-porphinato(2-)-kappaN21,kappaN22,kappaN23,kappaN24]-, (SP-4-1)-

C44H28N4Zn (676.1605)


   
   

[6-[5,7-Dihydroxy-4-oxo-8-(3,4,5-trihydroxyoxan-2-yl)-2-(2,4,5-trihydroxyphenyl)chromen-6-yl]-3,4,5-trihydroxyoxan-2-yl]methyl hydrogen sulate

[6-[5,7-Dihydroxy-4-oxo-8-(3,4,5-trihydroxyoxan-2-yl)-2-(2,4,5-trihydroxyphenyl)chromen-6-yl]-3,4,5-trihydroxyoxan-2-yl]methyl hydrogen sulate

C26H28O19S (676.0945)


   

PAPA

PAPA

C20H26N10O13P2 (676.1156)


A 5-phospho-(3->5)-dinucleotide composed from two AMP residues.

   

5-d(pGpG)-3

5-d(pGpG)-3

C20H26N10O13P2 (676.1156)


A single-stranded DNA oligonucleotide comprising two 2-deoxyguanosine residues connected by a 3->5 linkage and with a phosphoric group at the 5-terminus.

   
   

14-(4,4-dichloropentyl)-2,5-dihydroxy-18-(2-hydroxypropan-2-yl)-7-isopropyl-15,15-dimethyl-13,17-dioxa-9,20-dithia-3,6,22,23-tetraazatricyclo[17.2.1.1⁸,¹¹]tricosa-1(21),2,5,8(23),10,19(22)-hexaene-12,16-dione

14-(4,4-dichloropentyl)-2,5-dihydroxy-18-(2-hydroxypropan-2-yl)-7-isopropyl-15,15-dimethyl-13,17-dioxa-9,20-dithia-3,6,22,23-tetraazatricyclo[17.2.1.1⁸,¹¹]tricosa-1(21),2,5,8(23),10,19(22)-hexaene-12,16-dione

C28H38Cl2N4O7S2 (676.1559)


   

methyl 2-[3-({2,4-dihydroxy-3-[4-hydroxy-2-methoxy-6-(methoxycarbonyl)benzoyl]-6-methylphenyl}methyl)-2,6-dihydroxy-4-methylbenzoyl]-5-hydroxy-3-methoxybenzoate

methyl 2-[3-({2,4-dihydroxy-3-[4-hydroxy-2-methoxy-6-(methoxycarbonyl)benzoyl]-6-methylphenyl}methyl)-2,6-dihydroxy-4-methylbenzoyl]-5-hydroxy-3-methoxybenzoate

C35H32O14 (676.1792)


   

(2r,10r)-3,11,19-tris(4-hydroxyphenyl)-4,12,20-trioxaheptacyclo[16.6.1.1²,⁵.1¹⁰,¹³.0²¹,²⁵.0⁹,²⁷.0¹⁷,²⁶]heptacosa-1(25),5(27),6,8,13(26),14,16,18,21,23-decaene-7,15,23-triol

(2r,10r)-3,11,19-tris(4-hydroxyphenyl)-4,12,20-trioxaheptacyclo[16.6.1.1²,⁵.1¹⁰,¹³.0²¹,²⁵.0⁹,²⁷.0¹⁷,²⁶]heptacosa-1(25),5(27),6,8,13(26),14,16,18,21,23-decaene-7,15,23-triol

C42H28O9 (676.1733)


   

2-methoxy-6-sulfanyl-4-[(3,4,5-trihydroxy-6-{2-methoxy-4-[(3,4,5,6-tetrahydroxyoxan-2-yl)methoxy]phenoxy}oxan-2-yl)methoxy]phenyl methyl carbonate

2-methoxy-6-sulfanyl-4-[(3,4,5-trihydroxy-6-{2-methoxy-4-[(3,4,5,6-tetrahydroxyoxan-2-yl)methoxy]phenoxy}oxan-2-yl)methoxy]phenyl methyl carbonate

C28H36O17S (676.1673)


   

(2s,3s,10r,11r)-3-(3-hydroxyphenyl)-11,19-bis(4-hydroxyphenyl)-4,12,20-trioxaheptacyclo[16.6.1.1²,⁵.1¹⁰,¹³.0²¹,²⁵.0⁹,²⁷.0¹⁷,²⁶]heptacosa-1(25),5(27),6,8,13(26),14,16,18,21,23-decaene-7,15,23-triol

(2s,3s,10r,11r)-3-(3-hydroxyphenyl)-11,19-bis(4-hydroxyphenyl)-4,12,20-trioxaheptacyclo[16.6.1.1²,⁵.1¹⁰,¹³.0²¹,²⁵.0⁹,²⁷.0¹⁷,²⁶]heptacosa-1(25),5(27),6,8,13(26),14,16,18,21,23-decaene-7,15,23-triol

C42H28O9 (676.1733)


   

3,11,19-tris(4-hydroxyphenyl)-4,12,20-trioxaheptacyclo[16.6.1.1²,⁵.1¹⁰,¹³.0²¹,²⁵.0⁹,²⁷.0¹⁷,²⁶]heptacosa-1(25),5(27),6,8,13(26),14,16,18,21,23-decaene-7,15,23-triol

3,11,19-tris(4-hydroxyphenyl)-4,12,20-trioxaheptacyclo[16.6.1.1²,⁵.1¹⁰,¹³.0²¹,²⁵.0⁹,²⁷.0¹⁷,²⁶]heptacosa-1(25),5(27),6,8,13(26),14,16,18,21,23-decaene-7,15,23-triol

C42H28O9 (676.1733)


   

(7s,14s,18s)-14-(4,4-dichloropentyl)-2,5-dihydroxy-18-(2-hydroxypropan-2-yl)-7-isopropyl-15,15-dimethyl-13,17-dioxa-9,20-dithia-3,6,22,23-tetraazatricyclo[17.2.1.1⁸,¹¹]tricosa-1(21),2,5,8(23),10,19(22)-hexaene-12,16-dione

(7s,14s,18s)-14-(4,4-dichloropentyl)-2,5-dihydroxy-18-(2-hydroxypropan-2-yl)-7-isopropyl-15,15-dimethyl-13,17-dioxa-9,20-dithia-3,6,22,23-tetraazatricyclo[17.2.1.1⁸,¹¹]tricosa-1(21),2,5,8(23),10,19(22)-hexaene-12,16-dione

C28H38Cl2N4O7S2 (676.1559)


   

(2r,3r,10r,11r)-3,11,19-tris(4-hydroxyphenyl)-4,12,20-trioxaheptacyclo[16.6.1.1²,⁵.1¹⁰,¹³.0²¹,²⁵.0⁹,²⁷.0¹⁷,²⁶]heptacosa-1(25),5(27),6,8,13(26),14,16,18,21,23-decaene-7,15,23-triol

(2r,3r,10r,11r)-3,11,19-tris(4-hydroxyphenyl)-4,12,20-trioxaheptacyclo[16.6.1.1²,⁵.1¹⁰,¹³.0²¹,²⁵.0⁹,²⁷.0¹⁷,²⁶]heptacosa-1(25),5(27),6,8,13(26),14,16,18,21,23-decaene-7,15,23-triol

C42H28O9 (676.1733)


   

(2r,3r,10s,11s)-3,11,19-tris(4-hydroxyphenyl)-4,12,20-trioxaheptacyclo[16.6.1.1²,⁵.1¹⁰,¹³.0²¹,²⁵.0⁹,²⁷.0¹⁷,²⁶]heptacosa-1(25),5(27),6,8,13(26),14,16,18,21,23-decaene-7,15,23-triol

(2r,3r,10s,11s)-3,11,19-tris(4-hydroxyphenyl)-4,12,20-trioxaheptacyclo[16.6.1.1²,⁵.1¹⁰,¹³.0²¹,²⁵.0⁹,²⁷.0¹⁷,²⁶]heptacosa-1(25),5(27),6,8,13(26),14,16,18,21,23-decaene-7,15,23-triol

C42H28O9 (676.1733)


   

2-methoxy-6-sulfanyl-4-{[(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(2-methoxy-4-{[(2r,3s,4s,5r,6r)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy}phenoxy)oxan-2-yl]methoxy}phenyl methyl carbonate

2-methoxy-6-sulfanyl-4-{[(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(2-methoxy-4-{[(2r,3s,4s,5r,6r)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy}phenoxy)oxan-2-yl]methoxy}phenyl methyl carbonate

C28H36O17S (676.1673)


   

[(1r,7s,9r,16s,21r,23s)-16-(acetyloxy)-3,14,25-trihydroxy-21-(2-methoxy-2-oxoethyl)-7,23-dimethyl-5,12,27-trioxo-8,22-dioxaheptacyclo[14.11.1.0²,¹⁵.0⁴,¹³.0⁶,¹¹.0¹⁷,²⁶.0¹⁹,²⁴]octacosa-2,4(13),6(11),14,17(26),18,24-heptaen-9-yl]acetic acid

[(1r,7s,9r,16s,21r,23s)-16-(acetyloxy)-3,14,25-trihydroxy-21-(2-methoxy-2-oxoethyl)-7,23-dimethyl-5,12,27-trioxo-8,22-dioxaheptacyclo[14.11.1.0²,¹⁵.0⁴,¹³.0⁶,¹¹.0¹⁷,²⁶.0¹⁹,²⁴]octacosa-2,4(13),6(11),14,17(26),18,24-heptaen-9-yl]acetic acid

C35H32O14 (676.1792)


   

(2r,3s,10s,11s)-3,11,19-tris(4-hydroxyphenyl)-4,12,20-trioxaheptacyclo[16.6.1.1²,⁵.1¹⁰,¹³.0²¹,²⁵.0⁹,²⁷.0¹⁷,²⁶]heptacosa-1(25),5(27),6,8,13(26),14,16,18,21,23-decaene-7,15,23-triol

(2r,3s,10s,11s)-3,11,19-tris(4-hydroxyphenyl)-4,12,20-trioxaheptacyclo[16.6.1.1²,⁵.1¹⁰,¹³.0²¹,²⁵.0⁹,²⁷.0¹⁷,²⁶]heptacosa-1(25),5(27),6,8,13(26),14,16,18,21,23-decaene-7,15,23-triol

C42H28O9 (676.1733)


   

3-(3-hydroxyphenyl)-11,19-bis(4-hydroxyphenyl)-4,12,20-trioxaheptacyclo[16.6.1.1²,⁵.1¹⁰,¹³.0²¹,²⁵.0⁹,²⁷.0¹⁷,²⁶]heptacosa-1(25),5(27),6,8,13(26),14,16,18,21,23-decaene-7,15,23-triol

3-(3-hydroxyphenyl)-11,19-bis(4-hydroxyphenyl)-4,12,20-trioxaheptacyclo[16.6.1.1²,⁵.1¹⁰,¹³.0²¹,²⁵.0⁹,²⁷.0¹⁷,²⁶]heptacosa-1(25),5(27),6,8,13(26),14,16,18,21,23-decaene-7,15,23-triol

C42H28O9 (676.1733)